By Colin Kellaher
Shares of Stoke Therapeutics rose more than 7% in premarket trading Wednesday after the biotechnology company said it has received Food and Drug Administration breakthrough-therapy designation for its zorevunersen proposed treatment for a severe genetic epilepsy.
Stoke said the designation covers zorevunersen, which it is developing as a disease-modifying medicine, for the treatment of Dravet syndrome with a confirmed mutation, not associated with gain-of-function, in the SCN1A gene.
The FDA's breakthrough-therapy designation aims to expedite the development and review of a drug for serious conditions when preliminary clinical evidence shows the drug might offer substantial improvement over available therapies.
Stoke said talks with the FDA and other global regulatory agencies regarding a Phase 3 registrational study of zorevunersen continue, adding that it expects to provide an update on its study plans by the end of the year.
Shares of the Bedford, Mass., company, which closed Tuesday at $11.43, were recently up 7.2% at $12.25 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 04, 2024 07:39 ET (12:39 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。